Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibutamoren - Lumos Pharma/Merck

Next Previous
Drug Profile

Ibutamoren - Lumos Pharma/Merck

Alternative Names: Ibutamoren mesilate; Ibutamoren mesylate; L 163191; LUM-201; MK-0677; MK-677; Oratrope

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Lumos Pharma; Massachusetts General Hospital; Merck & Co
  • Class Antidementias; Hepatoprotectants; Indoles; Osteoporosis therapies; Small molecules; Spiro compounds
  • Mechanism of Action Growth hormone releasing factor agonists; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease; Somatotropin deficiency
  • Phase I Turner's syndrome
  • Discontinued Alzheimer's disease; Fibromyalgia; Fracture; Postmenopausal osteoporosis; Sarcopenia

Most Recent Events

  • 12 Apr 2024 Lumos Pharma has patent protection for Ibutamoren in Canada before April 2024 (Lumos Pharma, Form 10-K)
  • 12 Apr 2024 Lumos Pharma has patent protection for method of use of Ibutamoren for growth hormone deficiency disorders in USA before April 2024 (Lumos Pharma, Form 10-K)
  • 12 Apr 2024 Lumos Pharma has patents pending for method of use of Ibutamoren for growth hormone deficiency disorders in many countries (Lumos Pharma, Form 10-K)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top